Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 809-814

  Yamashita, Taro ^a   Fukushima, Toshihiro ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Carbonyl reducing enzyme; Idarubicin; Idarubicinol; Self potentiation

Indexed keywords

ANTHRACYCLINE CARBONYL REDUCING ENZYME; DOXORUBICIN; DRUG METABOLITE; ENZYME; IDARUBICIN; IDARUBICINOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; FISCHER 344 RAT; IN VITRO STUDY; IN VIVO STUDY; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT;

ALCOHOL OXIDOREDUCTASES; ANIMALS; ANTHRACYCLINES; CELL LINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IDARUBICIN; LIVER; PHARMACOKINETICS; RATS;

EID: 42049114942     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801947526     Document Type: Conference Paper

References (31)

1. Bonfante, V., Ferrari, L., Villani, F. and Bonadonna, G. (1983) Phase I study of 4-demethoxydaunorubicin. Invest New Drugs, 1, pp. 161-168.
2. Wiernik, P. H., Banks, P. L., Case Jr, D. C., Arlin, Z. A., Periman, P. O. and Todd, M. B. (1992) Cytarabine plus IDA or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79, pp. 313-319.
3. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T. and Kempin, S. (1991) Results of a randomized trial comparing IDA and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77, pp. 1666-1674.
4. Vogler, W. R., Velez-Garcia, E., Weiner, R. S., Flaum, M. A., Bartolucci, A. A. and Omura, G. A. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J Clin Oncol, 10, pp. 1103-1111.
5. Lovless, H., Arena, E., Felsted, R. L. and Bachur, N. R. (1978) Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res, 38, pp. 593-598.
6. Felsted, R. L. and Bachur, N. R. (1982) Human liver daunorubicin reductases. Prog Clin Biol Res, 114, pp. 291-305.
7. Wermuth, B., Bohren, K. M., Heinemann, G., von Wartburg, J. P. and Gabbay, K. H. (1988) Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J Biol Chem, 263, pp. 16185-16188.
8. Bohren, K. M., Bullock, B., Wermuth, B. and Gabbay, K. H. (1989) The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem, 264, pp. 9547-9551.
9. Wirth, H. and Wermuth, B. (1992) Immunohistochemical localization of carbonyl reductase in human tissues. J Histochem Cytochem, 40, pp. 1857-1863.
10. Forrest, G. L. and Gonzalez, B. (2000) Carbonyl reductase. Chem Biol Interact, 129, pp. 21-40.
11. Kuffel, M. J., Reid, J. M. and Ames, M. M. (1992) Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol, 30, pp. 51-57.
12. Bot, M A Le, Begue, J. M., Kernaleguen, D., Robert, J., Ratanasavanh, D. and Airiau, J. (1988) Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem Pharmacol, 37, pp. 3877-3887.
13. Gonzalez, B., Akman, S., Doroshow, J., Rivera, H., Kaplan, W. D. and Forrest, G. L. (1995) Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res, 55, pp. 4646-4650.
14. Soldan, M., Netter, K. J. and Maser, E. (1996) Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem Pharmacol, 51, pp. 117-123.
15. Ax, W., Soldan, M., Koch, L. and Maser, E. (2000) Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol, 59, pp. 293-300.
16. Tomida, A., Naito, M. and Tsuruo, T. (1995) Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin. Cancer Sci, 86, pp. 224-232.
17. Simon, S. M. and Schindler, M. (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA, 2691, pp. 3497-3504.
18. Skovsgaard, T., Nielsen, D., Maare, C. and Wassermann, K. (1994) Cellular resistance to cancer chemotherapy. Int Rev Cytol, 156, pp. 77-157.
19. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E. and Almquist, K. C. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, pp. 1650-1654.
20. Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. S. and van Heijningen, T. H. (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res, 53, pp. 1475-1479.
21. Fukushima, T., Kawai, Y., Urasaki, Y., Yoshida, A., Ueda, T. and Nakamura, T. (1994) Influence of idarubicinol on the antileukemic effect of idarubicin. Leuk Res, 18, pp. 943-947.
22. Tamassia, V., Pacciarini, M. A., Moro, E., Piazza, E., Vago, G. and Libretti, A. (1987) Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. Int J Clin Pharmacol Res, 7, pp. 419-426.
23. Robert, J. (1993) Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet, 24, pp. 275-288.
24. Fukushima, T., Yamashita, T., Goto, N., Ueda, T., Okabe, K. I. and Kuraishi, Y. (2001) A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: Relationship with leukocytopenia and neutropenia. Int J Hematol, 74, pp. 297-302.
25. Finkel, J. M., Knapp, K. T. and Mulligan, L. T. (1969) Fluorometric determination of serum levels and urinary excretion of daunomycin (NSC-82151) in mice and rats. Cancer Chemother Rep, 53, pp. 159-164.
26. Motoji, N., Hayama, E. and Shigematsu, A. (1995) Studies on the quantitative autoradiography. I. Radioluminography for quantitative autoradiography of 14C. Biol Pharm Bull, 18, pp. 89-93.
27. Moro, E., Bellotti, V., Jannuzzo, M. G., Stegnjaich, S. and Valzelli, G. (1983) High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative. J Chromatogr, 274, pp. 281-287.
28. Camaggi, C. M., Carisi, P., Strocchi, E. and Pannuti, F. (1992) High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol, 30, pp. 303-306.
29. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951) Protein measurement with the folin phenol reagent. J Biol Chem, 193, pp. 265-275.
30. Kang, W. and Weiss, M. (2003) Modeling the metabolism of idarubicin to idarubicinol in rat heart: Effect of rutin and phenobarbital. Drug Metab Dispos, 31, pp. 462-468.
31. Fukushima, T., Ueda, T., Uchida, M. and Nakamura, T. (1993) Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol, 57, pp. 121-130.